LON:NFX Nuformix (NFX) Share Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free NFX Stock Alerts GBX 0.20 +0.02 (+11.11%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range 0.18▼ 0.2050-Day Range 0.18▼ 0.2952-Week Range 0.18▼ 0.44Volume1.38 million shsAverage Volume2.28 million shsMarket Capitalization£1.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsStock AnalysisChartCompetitors Get Nuformix alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Nuformix Stock (LON:NFX)Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.Read More NFX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NFX Stock News HeadlinesNovember 16, 2023 | morningstar.comNuformix PLC NFXOctober 23, 2023 | lse.co.ukNuformix gets patent in Japan for pulmonary fibrosis treatment NXP002April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.October 5, 2023 | finance.yahoo.comNuformix to fund its unlicensed programs with NXP001 windfallJuly 25, 2023 | uk.investing.comCloud Village Inc (9899)July 15, 2023 | uk.investing.comK Seng Seng Corporation Bhd (KSSC)July 14, 2023 | uk.investing.comSuzumo Machinery Co Ltd (6405)July 13, 2023 | uk.investing.comENGAGE XR Holdings PLC (EXRE)April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 17, 2023 | lse.co.ukNuformix raises GBP70,000 to fund NXP002 programmeApril 17, 2023 | marketwatch.comNuformix Raises GBP70,000 in Discount Share SubscriptionMarch 27, 2023 | marketwatch.comNuformix Says Study Shows Effectiveness of New Lung-Disease Treatment CandidateMarch 13, 2023 | marketwatch.comNuformix to Change Financial Year End to Sept. 30December 20, 2022 | marketwatch.comNuformix Shares Rise on Positive Olaparib Cancer Treatment Study ResultsDecember 20, 2022 | proactiveinvestors.com.auNuformix delighted as NXP004 testing exceeds its expectationsDecember 13, 2022 | lse.co.ukNuformix interim loss virtually flat as continues work on drugsSeptember 23, 2022 | marketwatch.comNuformix to Start New NXP002 Study Program; Cancels Current Human IPF Tissue StudySeptember 17, 2022 | lse.co.ukLONDON MARKET EARLY CALL: Soft end to rocky week; UK retail sales dueAugust 10, 2022 | marketwatch.comNuformix Shares Rise on Completion of Pre-Clinical Tolerability Studies for NXP002 TreatmentJuly 28, 2022 | marketwatch.comNuformix 1H Pretax Loss Narrowed on Lower Costs; Shares RiseJune 27, 2022 | marketwatch.comNuformix to Continue Investigating NXP002 TreatmentMay 31, 2022 | lse.co.ukNuformix Executive Chair Alastair Riddell resigns after one yearMay 31, 2022 | ca.proactiveinvestors.comNuformix chairman resigns to take up new roleMay 30, 2022 | marketwatch.comNuformix Shares Drop After NXP002 Trial Results Were Inconsistent, Failure to Identify New ChiefMay 30, 2022 | ca.proactiveinvestors.comNuformix updates on NXP002, drug pipeline and CEO searchApril 12, 2022 | proactiveinvestors.comNuformix will receive a gross £1.32mln from second tranche of Lanstead funding agreementApril 5, 2022 | marketwatch.comNuformix Shareholder Raises Stake to 16.6%See More Headlines Receive NFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuformix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/22/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:NFX Previous SymbolLON:LVRT CUSIPN/A CIKN/A Webwww.levrett.com Phone44 1223 423 667FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-1,200,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.25% Return on Assets-17.20% Debt Debt-to-Equity Ratio1.17 Current Ratio1.51 Quick Ratio3.35 Sales & Book Value Annual Sales£50,000.00 Price / Sales32.44 Cash FlowGBX 0.06 per share Price / Cash Flow3.55 Book ValueGBX 1 per share Price / Book0.20Miscellaneous Outstanding Shares819,310,000Free FloatN/AMarket Cap£1.62 million OptionableNot Optionable Beta0.29 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Daniel John Gooding (Age 51)Executive Director Comp: $30kDr. Joanne M. Holland (Age 49)Consultant Comp: $66kMr. Benjamin HarberCompany SecretaryKey CompetitorsSalvaRx GroupLON:SALVReNeuron GroupLON:RENEPhysiomicsLON:PYCEvgen PharmaLON:EVGPort Erin Biopharma InvestmentsLON:PEBIView All Competitors NFX Stock Analysis - Frequently Asked Questions How have NFX shares performed in 2024? Nuformix's stock was trading at GBX 0.33 at the beginning of the year. Since then, NFX shares have decreased by 38.5% and is now trading at GBX 0.20. View the best growth stocks for 2024 here. How were Nuformix's earnings last quarter? Nuformix plc (LON:NFX) released its quarterly earnings results on Wednesday, July, 22nd. The company reported ($0.16) EPS for the quarter. What other stocks do shareholders of Nuformix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nuformix investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Acasti Pharma (ACST), Adamis Pharmaceuticals (ADMP) and Aldeyra Therapeutics (ALDX). How do I buy shares of Nuformix? Shares of NFX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:NFX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuformix plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
